Please login to the form below
Ryzodeg
This page shows the latest Ryzodeg news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk growth takes a hit with China deal
Novo has announced that it was successful in getting all its insulin products onto the national formulary with the exception of Ryzodeg and Xultophy. ... Ryzodeg contains a combination of long acting insulin degludec – which Novo markets as Tresiba –
Latest news
-
Novo seeks to strengthen Tresiba label in US
Interim results from the 7, 500-patient DEVOTE study were instrumental in allowing Novo to get FDA approval for Tresiba and combination drug Ryzodeg in 2015, after being knocked back by
-
Novo Nordisk's Tresiba gaining ground in basal insulin market
Nevertheless, the strong sales performance for Tresiba and other new insulin products - such as combination products Ryzodeg (insulin degludec/insulin aspart) and Xultophy (insulin degludec/liraglutide) - helped Novo Nordisk post a
-
Tresiba safer than insulin glargine, says Novo Nordisk
Last October however the Danish drugmaker finally won US approval for Tresiba and combination product Ryzodeg (insulin degludec and insulin aspart), prompting analysts at Sydbank to increase their peak sales predictions
-
Novo Nordisk finally bags insulin degludec approval in US
Ryzodeg, two drugs expected to consolidate its position as the leading diabetes company. ... Earlier this year however Novo Nordisk decided to refile Tresiba and Ryzodeg on the strength of interim data from the outcomes trial, called DEVOTE.
-
Novo brings Xultophy to third European market
US regulators dealt the company a major blow in February 2013 when marketing applications for Tresiba and Ryzodeg, which combines Tresiba with Novo's Novolog (insulin aspart), were rejected.
More from news
Approximately 6 fully matching, plus 15 partially matching documents found.
Latest Intelligence
-
Harnessing commercial innovation
products - such as basal insulin Tresiba and its Ryzodeg and Xultophy combinations.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn
- Landscape review reveals £1.1bn of UK funding for rare diseases
- Cancer Research UK partners with French cancer institute
- New diagnosis pathway has been launched to mark European Myeloma Day
- Impacting Lives with Rare Disease Education
- Sandoz biosimilar receives EC approval to treat MS
No results were found
PMHub
Genesis Research
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
